The DOI matches its Crossref record; 239 of the 239 references it cites were found in a registry or an index.
MicroRNAs: New Biomarkers for Diagnosis, Prognosis, Therapy Prediction and Therapeutic Tools for Breast Cancer
Open accessAbstract
Dysregulation of microRNAs (miRNAs) is involved in the initiation and progression of several human cancers, including breast cancer (BC), as strong evidence has been found that miRNAs can act as oncogenes or tumor suppressor genes. This review presents the state of the art on the role of miRNAs in the diagnosis, prognosis, and therapy of BC. Based on the results obtained in the last decade, some miRNAs are emerging as biomarkers of BC for diagnosis (i.e., miR-9, miR-10b, and miR-17-5p), prognosis (i.e., miR-148a and miR-335), and prediction of therapeutic outcomes (i.e., miR-30c, miR-187, and miR-339-5p) and have important roles in the control of BC hallmark functions such as invasion, metastasis, proliferation, resting death, apoptosis, and genomic instability. Other miRNAs are of interest as new, easily accessible, affordable, non-invasive tools for the personalized management of patients with BC because they are circulating in body fluids (e.g., miR-155 and miR-210). In particular, circulating multiple miRNA profiles are showing better diagnostic and prognostic performance as well as better sensitivity than individual miRNAs in BC. New miRNA-based drugs are also promising therapy for BC (e.g., miR-9, miR-21, miR34a, miR145, and miR150), and other miRNAs are showing a fundamental role in modulation of the response to other non-miRNA treatments, being able to increase their efficacy (e.g., miR-21, miR34a, miR195, miR200c, and miR203 in combination with chemotherapy).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Items 201–239 of 239
miRNAs in breast cancer tumorigenesis (Review)
ZHANG, Z. J., & Shi, L. (2011) · Oncology Reports · doi:10.3892/or.2011.1611 · Cited by 64
Oulas, A., Boutla, A., Gkirtzou, K., Reczko, M., Kalantidis, K., & Poirazi, P. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp120 · Cited by 64
Distribution Profiling of Circulating MicroRNAs in Serum
Ashby, J., Flack, K., Jiménez, L. A., Duan, Y., Khatib, A.-K., Somlo, G., Wang, S. E., Cui, X., & Zhong, W. (2014) · Analytical Chemistry · doi:10.1021/ac5028929 · Cited by 64
The role of microRNAs in human breast cancer progression
Zhang, W., Liu, J., & Wang, G. (2014) · Tumor Biology · doi:10.1007/s13277-014-2202-8 · Cited by 63
MicroRNA-510 promotes cell and tumor growth by targeting peroxiredoxin1 in breast cancer
Guo, Q. J., Mills, J. N., Bandurraga, S. G., Nogueira, L. M., Mason, N. J., Camp, E. R., LaRue, A. C., Turner, D. P., & Findlay, V. J. (2013) · Breast Cancer Research · doi:10.1186/bcr3464 · Cited by 63
Computational Methods for MicroRNA Target Prediction
Hamzeiy, H., Allmer, J., & Yousef, M. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-748-8_12 · Cited by 62
Lyng, M., Lænkholm, A., Søkilde, R., Thomsen, K. G., Litman, T., & Ditzel, H. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036170 · Cited by 61
Effect of microRNA-206 on Cytoskeleton Remodelling by Downregulating Cdc42 in MDA-MB-231 Cells
Liu, H., Cao, Y., Ye, W., & Sun, Y. (2010) · Tumori Journal · doi:10.1177/030089161009600518 · Cited by 60
The HER2-miR125a5p/miR125b loop in gastric and esophageal carcinogenesis
Fassan, M., Pizzi, M., Realdon, S., Balistreri, M., Guzzardo, V., Zagonel, V., Castoro, C., Mastracci, L., Farinati, F., Nitti, D., et al. (2013) · Human Pathology · doi:10.1016/j.humpath.2013.01.023 · Cited by 59
Capturing microRNA targets using an RNA-induced silencing complex (RISC)-trap approach
Cambronne, X. A., Shen, R., Auer, P. L., & Goodman, R. H. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1218887109 · Cited by 58
Madrigal, D. P., Finegan, K. G., Páramo, B., & Tournier, C. (2012) · Cellular Signalling · doi:10.1016/j.cellsig.2012.08.001 · Cited by 58
How microRNAs choose their targets
Hofacker, I. L. (2007) · Nature Genetics · doi:10.1038/ng1007-1191 · Cited by 57
miRRim: A novel system to find conserved miRNAs with high sensitivity and specificity
Terai, G., Komori, T., Asai, K., & Kin, T. (2007) · RNA · doi:10.1261/rna.655107 · Cited by 56
Micro-RNAs as clinical biomarkers and therapeutic targets in breast cancer: Quo vadis?
Christodoulatos, G. S. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i2.71 · Cited by 55
Selective repression of the oncogene cyclin D1 by the tumor suppressor miR-206 in cancers
Elliman, S. J., Howley, B. V., Mehta, D., Fearnhead, H. O., Kemp, D. M., & Barkley, L. R. (2014) · Oncogenesis · doi:10.1038/oncsis.2014.26 · Cited by 55
Winden, A. W. J. O., Rodenburg, W., Pennings, J. L. A., van Oostrom, C. T. M., Beijnen, J. H., Peeters, P. H. M., van Gils, C. H., & de Vries, A. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms131013587 · Cited by 55
Seviour, E. G., Sehgal, V., Lu, Y., Luo, Z., Moss, T. J. M., Zhang, F., Hill, S. M., Liu, W., Maiti, S. N., Cooper, L. J. N., et al. (2015) · Oncogene · doi:10.1038/onc.2014.469 · Cited by 52
Sandhu, R., Rein, J., D’Arcy, M. E., Herschkowitz, J. I., Hoadley, K. A., & Troester, M. A. (2014) · Carcinogenesis · doi:10.1093/carcin/bgu175 · Cited by 51
Li, Y., Hong, F., & Yu, Z. (2013) · Journal of International Medical Research · doi:10.1177/0300060513485856 · Cited by 49
Expression of Dicer and Drosha in triple-negative breast cancer
Passon, N., Gerometta, A., Puppin, C., Lavarone, E., Puglisi, F., Tell, G., Loreto, C. D., & Damante, G. (2012) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2011-200496 · Cited by 48
The involvement of microRNAs in malignant transformation.
Rutnam, Z. J., & Yang, B. B. (2012) · PubMed · doi:10.14670/hh-27.1263 · Cited by 47
microRNAs in cancer stem cells: current status and future directions
Chhabra, R., & Saini, N. (2014) · Tumor Biology · doi:10.1007/s13277-014-2264-7 · Cited by 47
Leung, C., Chen, T.-W., Li, S., Ho, M., Hu, L.-Y., Liu, W.-S., Wu, T. T.-L., Hsu, P., Chang, H.-T., & Tsai, K. (2014) · Oncology Reports · doi:10.3892/or.2014.3089 · Cited by 46
Bockhorn, J., Prat, A., Chang, Y.-F., Liu, X., Huang, S., Shang, M., Nwachukwu, C., Gomez-Vega, M. J., Harrell, J. C., Olopade, O. I., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1188 · Cited by 44
Computational methods for ab initio detection of microRNAs
Allmer, J., & Yousef, M. (2012) · Frontiers in Genetics · doi:10.3389/fgene.2012.00209 · Cited by 43
Gong, J., Luk, F., Jaiswal, R., & Bebawy, M. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00220 · Cited by 40
Bian, X.-J., Zhang, G.-M., Gu, C.-Y., Cai, Y., Wang, C.-F., Shen, Y.-J., Zhu, Y., Zhang, H. L., Dai, B., & Ye, D. (2014) · Tumor Biology · doi:10.1007/s13277-014-2462-3 · Cited by 37
Nassar, F. J., Sabban, M. E., Zgheib, N. K., Tfayli, A., Boulos, F. I., Jabbour, M. N., Saghir, N. S. E., Talhouk, R., Bazarbachi, A. A., Călin, G. A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107566 · Cited by 37
The locus of microRNA-10b: A critical target for breast cancer insurgence and dissemination
Biagioni, F., Moshe, N. B. B., Fontemaggi, G., Yarden, Y., Domany, E., & Blandino, G. (2013) · Cell Cycle · doi:10.4161/cc.25380 · Cited by 36
Li, J., Zhang, Y., Zhang, W., et al. (2013) · International Journal of Surgical Oncology · doi:10.1155/2013/875078 · Cited by 35
MicroRNA-21 as an Indicator of Aggressive Phenotype in Breast Cancer
Özgün, A., Karagöz, B., Bilgi, O., Tunçel, T., Baloğlu, H., & Kandemir, E. G. (2013) · Oncology Research and Treatment · doi:10.1159/000348678 · Cited by 34
Aberrant DNA methylation of microRNA genes in human breast cancer – a critical appraisal
Lehmann, U. (2014) · Cell and Tissue Research · doi:10.1007/s00441-014-1793-0 · Cited by 30
Shan, B. (2012) · Oncology Reports · doi:10.3892/or.2012.1764 · Cited by 22
Breast cancer-specific TRAIL expression mediated by miRNA response elements of let-7 and miR-122
Yan, Y., ZHANG, F., Fan, Q., LI, X., & Zhou, K. (2014) · Neoplasma · doi:10.4149/neo_2014_082 · Cited by 22
Khoshnaw, S. M., Rakha, E. A., Abdel-Fatah, T. M. A., Nolan, C. C., Hodi, Z., Macmillan, R. D., Ellis, I. O., & Green, A. R. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2358-0 · Cited by 19
Li, C., Nguyen, H. T., Zhuang, Y., Lin, Z. N., Flemington, E. K., Zhuo, Y., Kantrow, S. P., Morris, G. F., Sullivan, D. E., & Shan, B. (2012) · Gene · doi:10.1016/j.gene.2012.09.093 · Cited by 18
Saito, Y., Hashimoto, Y., Arai, M., Tarashima, N. S., Miyazawa, T., Miki, K., Takahashi, M. M., Furukawa, K., Yamazaki, N., Matsuda, A., et al. (2014) · ChemBioChem · doi:10.1002/cbic.201402398 · Cited by 17
Use of Serum-Circulating miRNA Profiling for the Identification of Breast Cancer Biomarkers
Mar‐Aguilar, F., Rodrı́guez-Padilla, C., & Reséndez‐Pérez, D. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-0856-1_6 · Cited by 16
Hua, X., Li, X., Yang, B., Zhang, L., Han, Z., & Han, C. (2014) · Tumor Biology · doi:10.1007/s13277-014-2587-4 · Cited by 13
Cited by
Lánczky, A., Nagy, Á., Bottai, G., Munkácsy, G., Szabó, A., Santarpia, L., & Győrffy, B. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-4013-7 · Cited by 768
Early Diagnosis of Breast Cancer
Wang, L. (2017) · Sensors · doi:10.3390/s17071572 · Cited by 549
Prognostic and predictive biomarkers in breast cancer: Past, present and future
Nicolini, A., Ferrari, P., & Duffy, M. J. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.08.010 · Cited by 424
SERS Tags for Biomedical Detection and Bioimaging
Liu, H., Gao, X., Xu, C., & Liu, D. (2022) · Theranostics · doi:10.7150/thno.66859 · Cited by 301
Precision medicine and radiogenomics in breast cancer: new approaches toward diagnosis and treatment
Pinker, K., Chin, J., Melsaether, A. N., Morris, E. A., & Moy, L. (2018) · Radiology · doi:10.1148/radiol.2018172171 · Cited by 275
Metadata
- Authors
- Bertoli, G., Cava, C., & Castiglioni, I.
- Venue
- Theranostics
- Publisher
- Ivyspring International Publisher
- Published
- 2015
- Volume
- 5
- Issue
- 10
- Pages
- 1122-1143
- ISSN
- 1838-7640 (ISSN-L)
- OpenAlex
- W2404879104
- Cited by
- 815
- References
- 239
- FWCI
- 24.83
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.